|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
For comparison, we evaluated 266 patients with advanced, ALK-negative, epidermal growth factor receptor (EGFR)-wild-type NSCLC, including 79 with KRAS mutations and 187 with wild-type KRAS (WT/WT/WT).
|
22887466 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Crizotinib appears to be efficacious and well tolerated in patients with NSCLC and may have future potential applications in treating lymphomas and other cancers driven by ALK or c-MET gene mutations.
|
23686600 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Anaplastic lymphoma kinase (ALK) fusion gene-positive lung cancer accounts for 4-5% of non-small cell lung carcinoma.
|
21757253 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Chromosomal translocations and single point mutations involving the Anaplastic Lymphoma Kinase (ALK) gene have been described in several human tumors, including anaplastic large cell lymphoma (ALCL), non-small cell lung cancer (NCSLC), inflammatory myofibroblastic tumor (IMT) and neuroblastoma.
|
22920921 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
|
22508824 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
At the moment, established personalized treatment approaches include treatment of patients with NSCLC and activating epidermal growth factor receptor (EGFR) mutations with the EGFR-directed tyrosine kinase inhibitors gefitinib or erlotinib, and treatment of NSCLC patients with genetic aberrations in the anaplastic lymphoma kinase (ALK) oncogene with the mesenchymal-epithelial transition factor (MET)/ALK inhibitor crizotinib.
|
22286583 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Current data on the efficacy and toxicity of crizotinib are also examined, and future directions for the treatment of NSCLC positive for ALK rearrangement are addressed.
|
22568572 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
We selected NSCLC cell lines--A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.
|
22617245 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
ROS1 rearrangements define a unique molecular class of lung cancers.
|
22215748 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS.
|
22787409 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.
|
22282074 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
While understanding molecular mechanisms of resistance is critical to overcome therapeutic resistance, understanding physiologic mechanisms of resistance through analyzing anatomic patterns of failure may be equally crucial to improve long-term survival for patients with EML4-ALK translocation positive NSCLC.
|
22986231 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
|
22277784 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Crizotinib, an inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), achieves response rates of 57 % at eight weeks in patients with stage IV non-small cell lung cancer with ALK rearrangements.
|
22713522 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
On August 2011, a small molecule inhibitor against ALK, crizotinib, was approved for therapy against NSCLC with ALK translocations.
|
22968692 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Crizotinib represents a new standard of care for patients with ALK-positive NSCLC and highlights the importance of the role of the pathologist, as molecular profiling becomes a part of initial workups for newly diagnosed patients with NSCLC.
|
23020724 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
|
22954507 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
It has been demonstrated that NSCLC driven by EML4-ALK is strongly addicted to this fusion-type oncokinase.
|
21767331 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Ongoing studies will define the true utility of this drug in ALK-rearranged non-small-cell lung cancer patients and in patients with other tumors that also have ALK activation.
|
21823889 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
In an ALK-enriched population, patients with metastatic non-small cell lung cancer were screened by ALK fluorescence in situ hybridization and for epidermal growth factor receptor (EGFR) and KRAS mutations.
|
21336183 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
We examined overall survival in patients with advanced, ALK-positive NSCLC who enrolled in the phase 1 clinical trial of crizotinib, focusing on the cohort of 82 patients who had enrolled through Feb 10, 2010.
|
21933749 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities.
|
21904575 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
We further identified a subset (3/50; 6%) of treatment naive NSCLC patients with ALK rearrangements that also had concurrent EGFR activating mutations.
|
21791641 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
A total of 465 formalin-fixed, paraffin-embedded non-small cell lung cancer samples were analyzed by ALK FISH (PathVysion, Vysis, Abbott) and ALK CISH.
|
21587085 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
|
21102269 |
2010 |